Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis
Sponsor: SIFI SpA
Listed as NCT03274895, this PHASE3 trial focuses on Acanthamoeba Keratitis and remains completed. Sponsored by SIFI SpA, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Nov 2022 — Sep 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Recruiting PHASE3
-
Oct 2017 — Sep 2018 [monthly]
Recruiting PHASE3
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SIFI SpA
For direct contact, visit the study record on ClinicalTrials.gov .